Microbot Medical creates and commercializes transformational micro-robotic medical technologies that can change the future of medicine.

Microbot Medical Research

Initiation of Pivotal Study

  • Commenced pivotal study for SCS in September 2018.
  • Includes a larger sample size, compared to the initial study, to validate positive outcome of initial study.
  • Primary and secondary endpoints will seek to validate the safety and efficacy of the SCS™ that will be activated in both in-vitro (lab) and in-vivo (animal) models.
  • After its anticipated publication in 2019, the pivotal study’s results is expected to support regulatory submission.

Self-Cleaning Shunt (SCSTM) In-Vitro Pre-clinical

  • Wayne State University:
    Goal: Test and finalize the design of the company’s SCS, using Dr. Carolyn Harris’ bioreactor system that mimics the human brain tissue three dimensionally.
    Results: Supports the SCS’s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.

Carolyn Harris, PhD

Harris Research Group

The Harris Research Group uses bioengineering approaches to study mechanisms and develop treatments for hydrocephalus. Our translational approach to research, integrating experimental bench top data with the expertise of clinicians and the experience of patients, brings a broad perspective to this complex disorder. Carolyn Harris received her BSE from Purdue University in 2006, and her Ph.D. in biomedical engineering from the University of Utah in 2011. She did her postdoctoral work at the University of Washington and began at Wayne State University in 2014. She has appointments in Chemical Engineering and Materials Science, Biomedical Engineering, and Neurosurgery.


  • Harris C, Pearson K, Trett K, Zhu S, Chong P, Taskin N, Shain W: Fabrication of three-dimensional hydrogel scaffolds for modeling cortical tissue obstruction in hydrocephalus Experimental Neurology (in preparation)
  • Harris C, Pearson K, Trett K, Zhu S, Chong P, Taskin N, Shain W : Retrograde Flushing Induced Shear Stress Reduces Astrocyte Attachment and Growth on Ventricular Catheters. Biomaterials (in preparation)
  • Harris C, Trett K, Chong P, Zhu S, Taskin N, Pearson K, Shain W : Electrophoresis as a novel method for increased antibody penetration through thick tissue samples. Nature Methods (in preparation)
  • Megjhani M, Mukherjee A, Rey N, Merouane A, Lu Y, Trett K, Chong P, Harris C, Shain W, Roysam B. IEEE Biomaterials (submitted April 2014)
    Harris C, McAllister JP II: What We Should Know About the Cellular and Tissue Response Causing Catheter Obstruction in the Treatment of Hydrocephalus (Review). Neurosurgery. 70(6): 1589-601, discussion 1601-2
  • Eskandari R, Harris CA, McAllister JP II: Reactive astrocytosis in feline neonatal hydrocephalus: acute, chronic, and shunt-induced changes. Child’s Nervous System. 27(12): 2067-76, 2011
  • Harris C, Resau J, Hudson E, West R, Moon C, Black AD, McAllister JP II: Reduction of Protein Adsorption and Macrophage and Astrocyte Adhesion on Ventricular Catheters by Polyethylene Glycol and N-Aceytl-L-Cysteine. Journal of Biomedical Materials Research Part A. 98(3):425-33, 2011
  • Harris C, McAllister JP II: Does drainage hole size influence adhesion on ventricular catheters? Child’s Nervous System. 27(8):1221-32, 2011
  • Harris C, Resau J, Hudson E, West R, Moon C, Black AD, McAllister JP II: Effects of surface wettability, flow, and protein concentration on macrophage and astrocyte adhesion in an in vitro model of central nervous system catheter obstruction. Journal of Biomedical Materials Research Part A. 97(4): 443-440, 2011
  • Harris C, Resau J, Hudson E, West R, Moon C, McAllister JP II: Mechanical contributions to astrocyte adhesion using a novel in vitro model of catheter obstruction. Experimental Neurology. 222(2):204-210, 2010
  • Black C, Resau J, West R, Grever W, McAllister JP II: Are We Implanting Shunt Catheters that Facilitate Shunt Failure? Fluids and Barriers of the CNS. 6 (Suppl 1):S42. (published abstract)
  • Wang A, Liang X, McAllister JP, Li J, Black C, Finlayson P, Cao T, Tang C, Salley S, Auner G, Ng KYS. 2007. Stability of and inflammatory response to silicon coated with a fluoroalkyl self-assembled monolayer in the central nervous system. Journal of Biomedical Materials Research Part A 81(2): 363-372, 2007
  • Wang A, McAllister JP II, Finlayson PG, Li J, Brabant KE, Tang H, Black CE, Cao T, Liang X, Salley SO, Auner GW, Ng KYS: Short- and long-term neural biocompatibility of heparin coated sapphire implants. Materials Science & Engineering C-Biomimetic and Supramolecular Systems. 27(2):237-243, 2007
  • Wang A, Cao T, Tang H, Liang X, Black C, Salley SO, McAllister JP II, Auner GW, Ng KYS. 2006. Immobilization of polysaccharides on a fluorinated silicon surface. Colloids and Surfaces B Biointerfaces 47(1): 57-63, 2006

Other Professional Experience


  • 2011-2014 – Postdoctoral Fellow – Center for Integrative Brain Research, Seattle Childrens Research Institute, Seattle, Washington
  • 2011 – Postdoctoral Fellow, Neurosurgery, University of Utah, Salt Lake City, Utah

Self-Cleaning Shunt (SCSTM) In-Vivo Pre-clinical

  • Washington University:
    Goal: Develop the protocol for and to execute the necessary animal study to determine the effectiveness of the company’s SCS™ prototype.
    Result: Met the primary goal to determine the safety of the company’s SCS™ device that aims to prevent obstruction in CSF catheters.

James (Pat) McAllister, PhD

McAllister  Laboratory

For nearly 30 years, Dr. McAllister’s lab has maintained a comprehensive interdisciplinary translational research program whose ultimate goal is to improve clinical treatments for hydrocephalus, a prevalent form of traumatic brain injury caused by failure to absorb cerebrospinal fluid (CSF). This program continues to explore the cellular and physiological neuropathology associated with neonatal, infantile and adult hydrocephalus and focuses on neuroinflammation, non-invasiveneuroimaging (MRI, diffusion tensor imaging, and MR elastography), pharmacological strategies for neuroprotection and recovery of function, and clinical evaluations of patient outcome and new treatment applications.

The multidisciplinary approach at McAllister Laboratory also includes biomedical engineering improvements in the design of CSF drainage systems (shunts), development of implantable sensors, and the biocompatibility of neural prostheses. Based on the recognition that treatment improvements for hydrocephalus have not progressed because of our lack of knowledge about the pathophysiology of this frequent disorder, James McAllister recently moved from the University of Utah to collaborate with David D. Limbrick, MD, PhD, a pediatric neurosurgeon at Washington University and a member of the Hope Center. Dr. Limbrick’s clinical research program is expanding to include several animal models of hydrocephalus: a porcine model to test the efficacy of a new neurosurgical procedure, combined endoscopic third ventriculostomy and choroidplexectomy; an infant ferret model to measure biomechanical changes during progressive hydrocephalus; a neonatal rat model of communicating hydrocephalus to explore all aspects of pathophysiology, and finally a congenital rat model of aqueductal stenosis to identify pathogenetic mechanisms and neurodevelopmental outcomes. All of these approaches will involve advanced neuroimaging, protein analyses of CSF, immunohistochemistry of brain tissue, and disease modulation with anti-inflammatory agents and chemokines.